STAT+: Pharmalittle: U.S. government blunder contributed to monkeypox vax shortage; Amgen to pay $4 billion for ChemoCentryx

Amgen will acquire ChemoCentryx for $4 billion to obtain a newly approved medicine that treats patients with a serious autoimmune condition.

Click to view original post